

1 **Title:** A genomic epidemiology study of multidrug-resistant *Escherichia coli*, *Klebsiella*
2 *pneumoniae* and *Acinetobacter baumannii* in two intensive care units in Hanoi, Vietnam

3
4 **Authors**

5 Leah W. Roberts^{1,2}, Le Thi Hoi^{3,4}, Fahad A. Khokhar², Nguyen Thi Hoa³, Tran Van Giang^{3,4},
6 Cuong Bui⁴, Tran Hai Ninh³, Dao Xuan Co⁵, Nguyen Gia Binh⁵, Hoang Bao Long⁴, Dang
7 Thi Huong³, James E. Bryan², Archie Herrick², Theresa Feltwell², Behzad Nadjm^{6,7}, H.
8 Rogier van Doorn^{7,8}, Julian Parkhill⁹, Nguyen Vu Trung^{3,4}, Nguyen Van Kinh³, Zamin
9 Iqbal^{1,*}, M. Estée Török^{2,10,*}

10 *Contributed equally

11

12 **Affiliations**

- 13 1. EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridge
14 2. Department of Medicine, University of Cambridge, Cambridge, United Kingdom
15 3. National Hospital for Tropical Diseases, Hanoi, Vietnam
16 4. Hanoi Medical University, Hanoi, Vietnam
17 5. Bach Mai Hospital, Hanoi Vietnam
18 6. Medical Research Council The Gambia at the London School of Hygiene & Tropical
19 Medicine, Fajara, The Gambia
20 7. Wellcome Trust Major Overseas Programme, Hanoi, Vietnam
21 8. Nuffield Department of Medicine, University of Oxford, Oxford, UK
22 9. Department of Veterinary Medicine, University of Cambridge, Cambridge, United
23 Kingdom
24 10. Departments of Infectious Diseases and Microbiology, Cambridge University
25 Hospitals NHS Foundation Trust, Cambridge, United Kingdom

26 **Correspondence**

27 M. Estée Török email: et317@cam.ac.uk

28 Zamin Iqbal, email: zi@ebi.ac.uk

29

30 **Key Words**

31 Antimicrobial resistance; whole genome sequencing; transmission; clusters; *Escherichia coli*;
32 *Klebsiella pneumoniae*; *Acinetobacter baumannii*; intensive care unit; Vietnam

33

34 **Abstract (298 words)**

35

36 Background

37 Vietnam has high rates of antimicrobial resistance (AMR) but limited genomic surveillance,
38 impeding our ability to assess transmission dynamics. This study aimed to use whole genome
39 sequencing (WGS) to examine the transmission of key AMR pathogens in two intensive care
40 units in Hanoi, Vietnam.

41 Methods

42 A prospective surveillance study of all adults admitted to two intensive care units (ICUs) at
43 the National Hospital for Tropical Diseases (NHTD) and Bach Mai Hospital (BMH) was
44 conducted between June 2017 and January 2018. Clinical and environmental samples were
45 cultured on selective media, characterised using MALDI TOF MS, and Illumina sequenced.
46 Phylogenies based on the *de novo* assemblies (SPAdes) were constructed using Mafft
47 (PARsnp), Gubbins and RAxML. Resistance genes were detected using Abricate against the
48 NCBI database.

49 Findings

50 3,153 *Escherichia coli*, *Klebsiella pneumoniae* and *Acinetobacter baumannii* isolates from
51 369 patients were analysed. Phylogenetic analysis revealed predominant lineages within *A.*
52 *baumannii* (global clone [GC]2, sequence types [ST]2, ST571) and *K. pneumoniae* (ST15,
53 ST16, ST656, ST11, ST147) isolates. Colonisation was most common with *E. coli* (88.9%)
54 followed by *K. pneumoniae* (62.4%). 91% of *E. coli* carried a *bla*CTX-M variant, while 81%
55 of *K. pneumoniae* isolates carried *bla*NDM (54%) and/or *bla*KPC (45%). Transmission
56 analysis using single nucleotide polymorphisms (SNPs) identified 167 clusters involving 251
57 (68%) patients, in some cases involving patients from both ICUs. There were no significant
58 differences between the lineages or AMR genes recovered between the two ICUs.

59 Interpretation

60 This study represents the largest prospective surveillance study of key AMR pathogens in
61 Vietnamese ICUs. Clusters of closely related isolates in patients across both ICUs suggests
62 recent transmission prior to ICU admission in other healthcare settings or in the community.

63 Funding

64 This work was funded by the Medical Research Council Newton Fund, United Kingdom; the
65 Ministry of Science and Technology, Vietnam (HNQT/SPDP/04.16) and the Wellcome Trust,
66 United Kingdom.

67

68

69 **Research in context (269):**

70

71 Evidence before this study:

72 Globally, antimicrobial resistance (AMR) is projected to cause 10 million deaths annually by
73 2050. While 90% of these deaths are expected to occur in African and Asian low- and
74 middle-income countries (LMIC), attributing morbidity and mortality is difficult without the
75 availability of comprehensive AMR data in these settings. Whilst efforts have been made to
76 improve AMR surveillance in these settings, this is often hampered by limited infrastructure,
77 training and financial resources.

78

79 Added value of this study:

80 This is the largest prospective surveillance study of three key AMR pathogens (*E. coli*, *K.*
81 *pneumoniae* and *A. baumannii*) conducted in critical care settings in Vietnam. All patients
82 were colonised or infected with one or more extended spectrum beta-lactamase (ESBL)
83 producing and/or carbapenem-resistant organism. Colonisation with more than one organism
84 was very common, with resistant *E. coli* predominantly isolated from stool. A small number
85 of predominant lineages were identified for *K. pneumoniae* and *A. baumannii*, while the *E.*
86 *coli* isolates were highly genetically diverse. A large number of genomic clusters were
87 identified within the two ICUs, some of which spanned both ICUs. There were no significant
88 differences between lineages or AMR genes between the two ICUs.

89

90 Implications of all the available evidence:

91 This study found high rates of colonisation and infection with three key AMR pathogens in
92 adults admitted to two Vietnamese ICUs. Whilst transmission was common within ICUs the
93 finding of similar lineages and AMR genes in both ICUs suggests that dissemination of AMR
94 occurs prior to ICU admission, from either referral sites or in community settings prior to
95 hospital admission. Strategies to tackle AMR in Vietnam will need to account for this by
96 extending surveillance beyond ICU to hospital and community settings.

97

98

99

100

101

102

103 **Introduction**

104 Low- and middle-income countries (LMICs) have reported widespread antimicrobial
105 resistance (AMR) in healthcare, community and agricultural settings. In South-East Asia,
106 dense human populations, intensive animal farming, unrestricted access to antibiotics and
107 limited laboratory infrastructure have all contributed to the rapid expansion of AMR (1, 2).

108

109 Much of this burden comes as a result of excessive use of antimicrobials in human and
110 animal populations. In Vietnam, antimicrobial usage has been estimated to be two times
111 higher in humans, and 1.5 times higher in animals, as compared to the European Union (3).
112 Despite legal restrictions in Vietnam, antibiotics are often dispensed without prescriptions in
113 the community (4). Broad-spectrum antibiotics are also commonly administered in healthcare
114 settings to mitigate the effects of limited capacity for microbiological testing and infection
115 control (4, 5). Detection of both resistant bacteria and antimicrobials have been recorded in
116 the environment (6, 7), hospital waste (8) and food sources (9, 10).

117

118 Extensive AMR has led to increased pressure on hospitals and is particularly problematic in
119 critical care settings. A study conducted in Thailand between 2008 and 2012 found that
120 almost 80% of nosocomial infections were caused by resistant bacteria, accounting for
121 roughly 100,000 AMR cases and 50,000 deaths annually (11). *Klebsiella pneumoniae* is
122 considered a dire threat because of high rates of AMR and virulence (12) and widespread
123 resistance to last-line treatments, such as carbapenems and polymyxins (13). *Acinetobacter*
124 *baumannii* is a leading cause of ventilator-associated pneumonia (VAP) in critically ill
125 patients, and is commonly treated with colistin due to widespread carbapenem resistance (14,
126 15).

127

128 Whilst AMR surveillance based on phenotypic antimicrobial susceptibility testing in Vietnam
129 has improved in recent years, the infrastructure required for systematic genomic surveillance
130 remains to be established. This is particularly important to determine circulating lineages and
131 elucidate potential transmission events, as other methods do not provide the same level of
132 resolution (16). Over the past decade, various studies have demonstrated the utility of WGS
133 in characterising AMR, transmission routes, and dominant lineages (17-19). LMICs however
134 remain relatively understudied, with few studies conducted in Vietnamese hospitals (20-23).
135 With increasing globalisation, understanding the dynamics of circulating lineages and

136 evolving AMR in these regions is necessary to address both local and global efforts to detect,
137 monitor and manage resistant bacterial infections.

138

139 In order to address this knowledge gap, we conducted a prospective genomic surveillance
140 study of key AMR pathogens in two hospitals in Vietnam. We targeted intensive care unit
141 (ICU) patients as we hypothesised that these would be most likely to have been treated with
142 antibiotics and to harbour AMR pathogens. Furthermore, we focussed our analysis on the
143 three most commonly isolated species (*Escherichia coli*, *K. pneumoniae*, and *A. baumannii*)
144 that were extended-spectrum beta-lactamase (ESBL) producers and/or carbapenem-resistant.
145 An additional in-depth analysis focussed primarily on a subset of the *K. pneumoniae* isolates
146 was also performed in a separate project (Pham et al., personal communication).

147

148 **Methods**

149 *Study design, setting and participants*

150 This prospective observational cohort study was conducted in two hospitals, the National
151 Hospital for Tropical Diseases (NHTD) and Bach Mai Hospital (BMH) in Hanoi, Vietnam,
152 between June 2017 to January 2018. All patients (aged 18 years or older) admitted to the
153 adult ICUs of the two hospitals were eligible for inclusion in the study. NHTD is a specialist
154 hospital for infectious and tropical diseases with a 22-bedded ICU which receives up to 400
155 patients per year. BMH is a large tertiary referral hospital, with a 45-bedded ICU that
156 receives up to 1,200 patients per year. Both hospitals are located in the same area of Hanoi
157 but operate independently of each other and do not share laboratory facilities, equipment or
158 staff. Patients are not commonly transferred between the two hospitals.

159

160 *Study procedures*

161 Screening specimens were collected from ICU patients on admission, on discharge and
162 weekly during their ICU stay. Specimens included stool/rectal swabs, urine, skin/wound
163 swabs and sputum/tracheal aspirates. Environmental samples were collected using flocked
164 swabs (from door handles, bed rails, medical equipment and patient tables) on a monthly
165 basis. Clinical data related to the ICU admission were collected from the medical records and
166 entered into a case record form and then into an electronic database. Laboratory data were
167 collected and recorded in an electronic database.

168

169 *Laboratory methods and sequencing*

170 All patient and environmental specimens were cultured on selective media (CHROMagar™
171 ESBL, CHROMagar™ mSuperCARBA™, CHROMagar™ VRE, CHROMagar, France).
172 Single colony picks of target organisms (*Escherichia coli*, *Acinetobacter baumannii* and
173 *Klebsiella pneumoniae*) were selected and identified using MALDI-TOF MS (Bruker
174 Diagnostics, Bremen, Germany) and stored at -80 °C. Stored isolates were shipped in two
175 batches to the University of Cambridge, United Kingdom, where they were sub-cultured, re-
176 identified using MALDI-TOF MS, and underwent antimicrobial susceptibility testing (Vitek-
177 2, BioMérieux, Marcy L'Étoile, France). Isolate DNA was extracted using QIACube and the
178 QIAamp 96 DNA QIACube HT kit (Qiagen, Hilden, Germany) prior to shipping to the
179 Wellcome Sanger Institute for sequencing. DNA was sequenced in two batches on an
180 Illumina HiSeq X10 machine (Illumina Inc., San Diego (CA), USA).

181

182 *Read quality control*

183 Raw Illumina reads were checked for quality using fastQC (v0.11.8) (24) and MultiQC (v
184 1.0.dev0) (25). Raw Illumina reads were also checked for contamination using Kraken2
185 (v2.0.7-beta) (26) and Bracken (v2.5) (27).

186

187 *Assembly*

188 Illumina reads were *de novo* assembled using SPAdes (v3.13.1) (28) and checked for quality
189 using Quast (v5.0.2) (29) and CheckM (v1.0.18) (30). Further filtering and quality control
190 methods for all assemblies is provided in the Supplementary Methods.

191

192 *Phylogenetic construction*

193 Prior to phylogenetic construction, reads were mapped to filtered assemblies and sites that
194 had <90% consensus compared to the reference allele were masked. Masked assemblies were
195 then aligned using PARsnp (v1.2) under default settings (31). Core multi-alignments
196 produced using PARsnp were filtered for recombination using Gubbins (v.2.3.5) (32).
197 Phylogenies were then constructed using RAxML (GTR-GAMMA model) (v8.2.12) (33) as
198 implemented through Gubbins. *E. coli* phylogroups were determined using ClermonTyping
199 (34). Trees were visualised using iTol v5.6.2 (35). Details on global reference selection are
200 provided in the Supplementary Methods.

201

202 *Antibiotic resistance gene detection*

203 Resistance genes and plasmid replicons were detected from draft assemblies using Abricate
204 (v1.0.1) (36) and the NCBI database (for resistance genes) (37). Genes were considered
205 present if there was 90% coverage at 90% nucleotide identity (38).

206

207 *Multi-locus sequence typing (MLST)*

208 Sequence types were determined using mlst (v2.19.0) (<https://github.com/tseemann/mlst>) and
209 the associated species scheme (specifically the Pasteur scheme for *A. baumannii*) (39-41).

210

211 *Transmission cluster analysis*

212 Transmission clusters were constructed using Transcluster (using the makeSNPClusters
213 method, which ignores time of sampling and uses a pure SNP-distance cut-off) (42) using
214 single nucleotide polymorphisms (SNPs) determined after recombination filtering using
215 Gubbins. Transmission cut-offs were evaluated based on intra- and inter-patient SNP
216 diversity within each species phylogeny (Supplementary Figure 1).

217

218 **Results**

219 *Samples included in the study*

220 Between June 2017 to January 2018, a total of 3,367 isolates were cultured, comprising
221 *Escherichia coli* (n=765), *Klebsiella pneumoniae* (n=1,372) and *Acinetobacter baumannii*
222 (n=1,230). Thirty-one isolates were excluded from the analysis because of poor assembly
223 quality. A further 150 isolates were excluded because of suspected inter-species
224 contamination, and 33 isolates were excluded because of suspected intra-species (strain-level)
225 contamination (Supplementary Figure 2). Thus 3,153 isolates (93.6%), comprising 2,901
226 isolates from 369 patients and 252 environmental isolates, passed quality filtering and were
227 included in the final analyses.

228

229 *Clinical data*

230 Of the 3,153 isolates, 1,042 (33%) were collected from BMH, while 2,111 (67%) were
231 collected from NHTD (Table 1). Both hospitals recruited a similar number of patients and the
232 average age was 53-55 years (BMH median age 55, NHTD median age 57.5). The average
233 length of stay (LOS) in BMH was 7 days (median 6 days), and 21 days (median 16 days) at
234 NHTD (Supplementary Figure 3). Patient outcomes are summarised in Table 1.

235

236

237

238

239

240 **Table 1: Summary of isolates and patients included in the study**

Variable	Bach Mai Hospital	National Hospital of Tropical Diseases
<i>Isolates:</i>		
Total	1042	2111
Clinical	993 (95%)	1898 (90%)
Environmental	49 (5%)	213 (10%)
<i>Patients:</i>		
Total	182	187
Male	104 (57%)	114 (61%)
Female	71 (39%)	50 (27%)
Gender not recorded	7 (4%)	23 (12%)
<i>Age:</i>		
Male	53 years (range 16-85)	55.2 years (range 5-92)
Female	53.4 years (range 19-91)	55.7 years (range 10-90)
Age not recorded	n=5 (3%)	n=19 (10%)
<i>Length of stay:</i>		
	7.5 days (range 0 – 35)	21 days (range 1 – 75)
Stay not recorded	n=4 (2.2%)	n=7 (3.7%)
<i>Outcome at discharge from ICU</i>		
Stable, discharged home	10 (6%)	38 (20%)
Improved, transferred to another ward	117 (64%)	83 (44%)
Deteriorated, transferred to another ward	3 (2%)	7 (4%)
Discharged home to die	44 (24%)	43 (23%)
Died in hospital	4 (2%)	9 (5%)
Not recorded	4 (2%)	7 (4%)

241

242

243

244

245

246 All of the 369 patients were colonised or infected with one or more of the three species: *E.*
247 *coli*, *A. baumannii* and *K. pneumoniae*: 146 patients (40%, 55 at BMH and 91 at NHTD)
248 were colonised or infected with all three species; 133 patients (36%, 66 at BMH and 67 at
249 NHTD) were colonised or infected with two of the three species; and 90 patients (24%, 61 at
250 MNH and 29 at NHTD) only had one species detected.

251

252 Both *E. coli* and *K. pneumoniae* were isolated primarily from stool / rectal swabs (627/721
253 [87.0%] and 822/1316 [62.5%], respectively). *K. pneumoniae* was also isolated from other
254 sites including sputum (325/1316 [24.7%]), urine samples (63/1316 [4.8%]) and skin swabs
255 (17/1316 [1.3%]). In contrast, *A. baumannii* isolates were mostly isolated from sputum
256 (621/1116 [55.6%]), followed by stool / rectal swabs (247/1116 [22.1%]), urine (49/1116
257 [4.4%]) and skin swabs (36/1116 [3.2%]). *A. baumannii* also accounted for the highest
258 number of environmental isolates (161/1116, [14.4%]), compared to 6.5% (85/1316) for *K.*
259 *pneumoniae* and 2.2% (16/721) for *E. coli*.

260


261 *Whole genome sequencing reveals predominant circulating lineages*

262 Phylogenetic trees for each species were constructed to explore lineage diversity within the
263 dataset. The *E. coli* isolates were found to be genomically diverse, with isolates spread over
264 eight phylogroups and 80 sequence types (STs) (Figure 1). The most prevalent ST was ST648
265 (phylogroup A; 11.8%), followed by ST410 (phylogroup C; 9.7%), ST617 (phylogroup A;
266 9.2%), ST131 (phylogroup B2; 7.9%) and ST1193 (phylogroup B2; 7.4%). Overall, 33 of the
267 80 STs only had one representative isolate in this dataset.

268

269 In contrast, the *K. pneumoniae* and *A. baumannii* isolates appeared to be centred around
270 specific dominant lineages. More than 80% of the *K. pneumoniae* isolates were from one of
271 five STs, including ST15 (n=34%), ST16 (n=20%), ST656 (n=12%), ST11 (n=11%) and
272 ST147 (n=7%). The majority of *A. baumannii* were global clone (GC)2 (n=832, 74.6%) (43)
273 and mainly belonged to ST2 (n=48%) and ST571 (n=24%) (based on the Pasteur scheme).
274 There did not appear to be any relationship between STs and hospitals, with all of the major
275 ST lineages detected in both ICUs.

276



277

278 **Figure 1: Whole genome phylogenies for [A] *E. coli*, [B] *A. baumannii*, and [C] *K. pneumoniae*:**
279 recombination-filtered core-SNP trees with mid-point root. Tree metadata includes (from left to right column
280 beside trees): MLST, source and hospital. Outermost purple bars indicate environmental isolates. Branches
281 corresponding to *E. coli* phylogroups are coloured accordingly. Main STs are highlighted in the image using the
282 pale-yellow boxes.

283

284

285

286 In order to gain broader insight into the lineages, we selected globally representative strains
287 to contextualise our dataset. Addition of these global representatives into the *E. coli*
288 phylogeny showed that most isolates belonged to a globally diverse set of STs that were not
289 unique to Vietnam, but found across parts of North America, Europe and Asia
290 (Supplementary Figure 4). Similarly, several of the major *K. pneumoniae* lineages were
291 represented globally, particularly ST147, ST11 (mainly from China and the USA) and ST15
292 (mainly Asian countries) (Supplementary Figure 5). However, it was also clear that local
293 expansion was prominent, particularly among the ST656, ST16 and ST15 lineages. For *A.*
294 *baumannii*, we focused primarily on GC2 isolates (Supplementary Figure 6). There was very
295 little representation of global strains similar to lineages within our dataset, and those that
296 were available consisted mainly of strains from other parts of Asia.

297


298 Closer inspection of the global representatives found several strains in each species that were
299 closely related (<5 core SNPs) to isolates in our dataset (Supplementary Table 1). Most of
300 these global representatives were also isolated in Asian countries. The exception was *E. coli*,
301 where two closely related global representatives were from the United Kingdom and
302 Australia (ST1193 and ST131, respectively). Agricultural isolates were also linked to these
303 lineages, as the other two closely related *E. coli* representatives were originally isolated from
304 poultry (biosample SAMEA104188722) and a farm worker in Vietnam (biosample
305 SAMEA5277968).

306

307 *High prevalence of antibiotic resistance genes among majority of isolates*

308 Almost all isolates carried acquired resistance genes belonging to at least 3 antibiotic classes,
309 with 90% of *E. coli*, 97% of *K. pneumoniae* and 41% *A. baumannii* carrying genes across 5
310 antibiotic classes (Figure 2). There were no discernible differences based on sample source or
311 hospital, with the exception of *E. coli* detected in pus/skin swabs (n=6) which appeared on
312 average to carry resistance to more antibiotic classes. *K. pneumoniae* isolates tended to fall
313 into one of three “peaks” (Figure 2). This was due to lineage-specific carriage of acquired
314 resistance genes, where ST15 isolates tended to carry resistance to more classes, compared to
315 ST16 which often carried the least. The other three main lineages (ST656, ST11, ST147) fell
316 between these two peaks. The exception was in the environmental samples, where only two
317 peaks can be seen. This is likely due to very few ST16 isolates detected in the environment.

318



319

320 **Figure 2:** Summary of isolates and the number of antibiotic resistance classes separated by species, hospital and
321 sample type.

322

323 Resistance to antibiotics classes varied across the *E. coli* phylogeny, reflective of the
324 diversity of strains within the dataset (Supplementary Figure 7). *bla*CTX-M genes were
325 found in most *E. coli*, with *bla*CTX-M-15 (36%), *bla*CTX-M-27 (30%) and *bla*CTX-M-55
326 (17%) the most prevalent (Table 2). *bla*KPC-2 (13%) and *bla*NDM-[1,4,5,7] (24%) were
327 present sporadically across the phylogroups, suggesting independent acquisitions events.
328 Only 4% (n=28) of isolates carried *mcr* genes conferring resistance to colistin. Again, these
329 seemed to be independent acquisitions, with the exception of an ST206 cluster (phylogroup
330 A; n=11) involving three patients from NHTD.

331

332 Conversely, MDR gene presence across the *K. pneumoniae* isolates appeared consistent with
333 the main lineages, suggesting clonal expansion rather than diverse sampling of the species

334 (Supplementary figure 8). Similar to the *E. coli*, incidence of *bla*CTX-M-15 (37.5%) was
335 high, but less so overall compared to *bla*KPC-2 (45%) and *bla*NDM (54%) (NDM-4 [27.9%],
336 NDM-1 [24.7%] and NDM-5 [1.8%]) (Table 2).

337

338 Acquired AMR genes were overall less prevalent among the *A. baumannii* isolates. Similar to
339 the *K. pneumoniae*, resistance to specific classes tended to be a feature of each distinct
340 lineage, suggesting clonal expansion (Supplementary Figure 9). The carbapenemase gene
341 *bla*OXA-23 was present in 83% of the dataset, with *bla*OXA-58 and *bla*OXA-72 present at
342 much lower frequencies (5% and 0.2% respectively) (Table 2). The aminoglycoside
343 resistance gene *armA* was also highly prevalent (76%).

344

345 Overall, 133 AMR genes were detected in BM and 154 were detected in NHTD. 49 genes
346 were unique to either hospital (35 in NHTD, 14 in BM), but were only detected at a
347 prevalence of less than 0.1%, suggesting sporadic cases. The remaining 129 genes were the
348 same across both hospitals. The genes with the highest prevalence (at least 1%) were found to
349 be almost identical in both hospitals, with the exception of *bla*NDM-4 (0.98%), *dfrA12*
350 (0.92%), *rmtB1* (0.86%), *qnrB6* (0.74%) and *bla*OXA-181 (0.56%) which were below 1%
351 prevalence in NHTD.

352

353 In order to determine if certain time points throughout the study had different gene burdens
354 (potentially indicative of mobile genetic element [MGE]-mediated transmission), we plotted
355 gene presence versus date for genes equivalent to 1% prevalence in either hospital
356 (Supplementary Figures 10). Overall, we found that both ICUs had a consistently high
357 burden, making it difficult to distinguish significant gene fluctuations over time. In NHTD,
358 we observed three genes that seemed to peak between November to December 2017.
359 Examination of our dataset for isolates with these three genes (*bla*NDM-4, *bla*OXA-181 and
360 *rmtB1*) revealed a subset of ST16 *K. pneumoniae* that carried all three genes as well as a
361 single ST11 isolate from BM. We plotted the presence of these isolates over time, which
362 mirrored the rise in prevalence in NHTD over the November to December period
363 (Supplementary Figure 11). No *E. coli* nor *A. baumannii* isolates in this dataset carried all
364 three genes.

365

366

367

368

369

370 **Table 2: Summary of resistance genes found in the three species**


Resistance gene class	<i>Escherichia coli</i>	<i>Acinetobacter baumannii</i>	<i>Klebsiella pneumoniae</i>
Tetracycline	563 (78.1%)	701 (62.8%)	753 (57.2%)
Sulphonamide	649 (90%)	746 (66.8%)	969 (73.6%)
Fluoroquinolone	161 (22.3%)	19 (1.7%)	1187 ³ (90.2%)
Colistin	28 (3.9%)	0 (0%)	10 (0.8%)
Fosfomycin	48 (6.7%)	5 (0.4%)	1316 ³ (100%)
MLS	579 (80%)	816 (73.1%)	623 (47.3%)
Trimethoprim	621 (86.1%)	41 (3.7%)	982 (74.6%)
Phenicols	274 (38%)	176 (15.8%)	675 (51.3%)
Bleomycin	179 (24.8%)	36 (3.2%)	717 (54.5%)
β-lactamase	718 (99.6%)	1018 (91.2%)	1286 (97.7%)
<i>Class C:</i>			
EC	721 ¹	2	0
ACT	0	1	0
CMY	209	1	2
DHA	26	2	24
<i>Class A:</i>			
LAP	17	0	142
CARB	0	63	0
PER	0	68	0
TEM	347	697	686
SHV	7	9	1292 ³
VEB	0	12	3
CTX	613	4	681
KPC	94	3	593
<i>Class D:</i>			
OXA	251	996 ²	611
<i>Class B:</i>			
IMP	0	6	1
NDM	173	35	716
Rifamycin	114 (15.8%)	63 (5.6%)	810 (61.6%)
Aminoglycoside	680 (94.3%)	1115 (99.9%)	1290 (98%)
Streptothricin	11 (1.53%)	8 (0.7%)	0 (0%)

371 ¹ blaEC intrinsic in *E. coli*

372 ² blaADC and blaOXA intrinsic in *A. baumannii* (except OXA-[1,10,23,58,72])

373 ³ fosA (fosfomycin), oqxAB (fluoroquinolone) and blaSHV intrinsic in *K. pneumoniae*
 374 ESBL resistance genes are highlighted in grey and carbapenem resistance genes in yellow
 375 *Most patients carried several AMR strains*
 376

377 Over half of the patients in this study had multiple isolates of the same species during their
 378 stay (*E. coli*: 51%, *K. pneumoniae*: 57%, *A. baumannii*: 58%). Of these patients, 60-70% had
 379 different sequence types (ST) (*E. coli*: 67%, *K. pneumoniae*: 68%, *A. baumannii*: 64%)
 380 (Figure 3). For *E. coli* and *K. pneumoniae*, the majority of patients only had isolates detected
 381 in stool (80% and 54%, respectively). Conversely, most patients with *A. baumannii* were
 382 detected only in sputum (38%), or sputum and stool (32%).
 383
 384



385
 386 **Figure 3: Overview of strain diversity, recurrence and source among study patients:** “Patients” refers to
 387 the total number of patients in this study that had at least one isolate of that species. Within each species, we
 388 evaluated whether patients had (i) only a single isolate for that species, or (ii) multiple isolates. If only a single
 389 isolate, we determined whether it was collected on admission to the ICU or after. For multiple isolates, we
 390 determined if the patient’s isolates were the same ST (recurrent) or a different ST. We finally looked at how

391 many patients had isolates from one site (urine, swab, stool or sputum) or mixed sites (any combination of
392 sites).

393

394 *Evidence of extensive transmission between ICU patients*

395 Temporal observation of the isolates found no obvious association of any time point with any
396 ST to suggest an outbreak of a specific lineage. In order to investigate potential clusters
397 within the ICUs at a higher resolution, we examined plausible short-term transmission events
398 using single nucleotide polymorphisms (SNPs).

399

400 To identify closely related strains that could indicate recent transmission, we evaluated
401 clusters based on SNP distances across the core genome of each species for this dataset.
402 Given the short sampling period, none of the three major species were likely to acquire more
403 than 1 SNP while in the hospital. As such, we looked at samples with genomic evidence of
404 most recent transmission; zero SNP clusters. Clusters were defined when they involved >1
405 patient. Clusters involving a single patient and environmental samples were not included.


406

407 Most clusters were detected in *K. pneumoniae* and *A. baumannii* isolates, with 71 and 74
408 clusters representing 38% and 52% of total isolates for that species, respectively (Figure 4).
409 *K. pneumoniae* had some of the largest clusters, ranging in size from 2 to 79 isolates, while *A.*
410 *baumannii* clusters were smaller, between 2 to 33 isolates. Only 22 clusters were detected in
411 *E. coli* and were generally small (median 3 isolates, range 2 to 9 isolates), representing only
412 13% of the *E. coli* dataset.

413

414 For all three species, the majority of clusters were detected between patients within a single
415 ICU. Evaluating admission and discharge dates further confirmed patient overlap in these
416 clusters (Figure 4, Supplementary Figures 12 to 17).

417



418

419

Figure 4: Summary of 0 SNP clusters in all species: Clusters were defined as (i) multiple patients: samples were derived from at least two different patients, or (ii) same patient: isolates were derived from the same patient, or only a single patient and the environment. Epidemiological evidence to support clusters was defined as (i) confirmed patient overlap: all patient ICU stays overlap with another in the same cluster, (ii) some patient overlap: at least 2 patient ICU stays overlap, and (iii) zero patient overlap between all patients in cluster. ENV isolate in clusters: clusters were counted if an environmental isolate was found in that cluster. Colonisation vs. infection: clusters were counted if they (a) had only isolates from stool (i.e. colonisation) or (b) had isolates from urine, swabs and/or sputum with or without isolates from stool (i.e. infection).

427

428

A. baumannii clusters were most often associated with environmental isolates (24/74 clusters, Figure 4). The largest *A. baumannii* cluster within the same hospital ICU involved 33 isolates from eight patients and eight environmental samples (Supplementary Figure 13; ST451, cluster number 13). Admissions for patients in this cluster overlapped with detection of the same strain in the environment, which was also detected in the hospital environment several months later. Only two *E. coli* clusters contained related environmental isolates. *K. pneumoniae* environmental isolates were more often found in within-hospital (ICU) clusters (n=11) compared to between-hospital clusters (n=4).

436

437

To broadly evaluate infection risk for each outbreak cluster, we determine whether clusters contained (i) stool sample / rectal isolates only, indicating colonisation or (ii) isolates from urine, skin swab or sputum samples, which could represent infection or colonisation at

439

440 multiple sites. The majority of *A. baumannii* clusters contained isolates from non-stool /
441 rectal swab samples (Figure 4). Conversely, colonisation-only clusters were common for *E.*
442 *coli*; the largest *E. coli* cluster involving both hospital ICUs contained only 5 isolates from
443 four patients, which were all isolated from stool (Supplementary Figure 14; ST617, cluster
444 number 37). *K. pneumoniae* clusters were a mix, with both colonisation-only clusters and
445 infection clusters.


446

447 In addition to suspected within-ICU transmission, we also detected a number of clusters
448 involving patients from both hospital ICUs (Figure 4). The most pronounced example of this
449 was a large ST15 *K. pneumoniae* cluster involving 79 isolates from 38 patients and 6
450 environmental samples (Supplementary Figure 18). Most were collected between July to
451 September, with some late occurrences in October and November. All patients from NHTD
452 between July to September had overlapping timelines, consistent with spread within the ICU
453 (Supplementary figure 16; ST15, cluster number 15). Only one patient had no evidence of
454 overlap (ND162) but did cluster with environmental isolates from the same timeframe,
455 indicating a possible environmental source. Patients from BM appeared to have both patient
456 overlap and consecutive acquisitions without patient overlap as time progressed. This
457 suggests that patient transmission and also transmission via other routes (e.g. inadequate
458 cleaning before the next patient, transmission via healthcare workers) may have been
459 important factors in the spread of this strain.

460

461 The identification of closely related isolates between independently operating ICUs
462 suggested that there may have been a common source located outside the ICU e.g admission
463 to the same location prior to admission to ICU. To determine if certain lineages were more
464 associated with acquisition within the ICU, we assessed diversity on arrival (i.e. the patients
465 first sample) versus diversity within the ICU (all other samples). Based on ST alone, we
466 found a slight increase in diversity in the ICU versus on arrival (Supplementary Figure 19).
467 However, the unique STs recovered in either setting only represented a small portion of the
468 isolates overall. All of the main lineages for each species were found on both admission and
469 within the ICU (Supplementary Figure 19 and 20).

470



471

472

Figure 5: Scatterpie showing the number of clusters in patients across all species: y-axis represents patients
473 from BM or NHTD involved in at least one 0 SNP cluster. X-axis represents length of stay for that patient; one
474 pie is plotted per patient at the duration of their stay. Each circle represents 0 SNP clusters in a single patient.
475 The size of the clusters corresponds to the number of clusters, while the colour relates to the species. The left
476 plot shows all 0 SNP clusters, while the right plot shows clusters condensed at 5 SNPs.

477

478

479

480

481

482

483 *Identification of multiple transmission clusters per patients*

484 Overall, there were 251 patients (representing 68% of the cohort) involved in 167 clusters
485 across the three species collected over the course of this study. 112 patients were only
486 involved in a single cluster during their time in the ICU (Figure 5). However, the remaining
487 139 patients were involved in at least two clusters, with one patient involved in 12 clusters
488 detected at 0 SNPs. For patients with at least two clusters, 20 had clusters from all three
489 species, 94 had clusters from two species and 25 had only one species. Overall, we saw a
490 general trend towards more clusters in a single patient as they spent more time in the ICU
491 ward.

492

493 To determine if our clusters were potentially derived from a single original cluster predating
494 their time in the ICU, we looked at SNP distances between clusters of the same ST
495 (Supplementary Figure 21). At a threshold of five SNPs, several of the prominent STs within
496 each species formed large clusters, including ST804 in *A. baumannii* and ST16 in *K.*
497 *pneumoniae*. At this threshold, we found 29 clusters in the *A. baumannii* dataset (originally
498 74), 23 clusters in the *K. pneumoniae* (originally 71) and 19 clusters in *E. coli* (originally 22).
499 By readjusting our analysis per patient using these clusters, we found that 123 patients had
500 only a single cluster during their stay (Figure 5). 128 patients had 2 clusters, with the
501 maximum number of clusters in a single patient being 7 (n=3 patients).

502

503

504 **Discussion**

505 Here we present a large prospective surveillance study of three key AMR pathogens from
506 two hospital ICUs in Vietnam. We used WGS to capture a high-resolution snapshot of the
507 dominant circulating lineages over a six-month period. In this study we focused on *E. coli*, *K.*
508 *pneumoniae*, and *A. baumannii*, as these were the most commonly isolated species from both
509 ICUs. These three species have also been reported as highly prevalent in other Vietnamese
510 studies (44), and are amongst the most clinically significant Gram-negative bacteria, having
511 been designated as “critical” priority pathogens for research and development of new
512 antibiotics by the World Health Organisation (45).

513

514 Phylogenetic analysis of all three species suggested local dominance of specific lineages for
515 *K. pneumoniae* and *A. baumannii*. Comparison to global representatives found few closely
516 linked strains, with an overall preference for local clustering. This was particularly evident

517 for *K. pneumoniae* ST15, ST656, ST11 and ST16 and many of the GC2 isolates for *A.*
518 *baumannii*. One notable exception was from a study conducted in southern Vietnam (46),
519 where a number of GC2 *A. baumannii* strains were found to be closely related to ST571
520 isolates from this study. Similar studies in other Vietnamese hospital settings have also
521 identified *K. pneumoniae* isolates corresponding to ST15 (23), ST16 (47) and ST11 (48) with
522 similar antimicrobial resistance profiles carrying *blaKPC* and *blaNDM*. This suggests that
523 these lineages may not be restricted to referral hospitals in Hanoi but may potentially occur
524 throughout Vietnam. In contrast, analysis of the study *E. coli* isolates and comparison with
525 global references did not identify evidence for locally dominant lineages, instead showing
526 large dispersal of global strains throughout the phylogeny.

527

528 Despite limiting our study samples to ESBL-producing and/or carbapenem-resistant isolates
529 belonging to three species, we identified a large number of isolates with an average of 16.55
530 and 9.68 isolates/day from patients in BMH and NHTD, respectively. This is an exceedingly
531 high number compared to other countries, such as the United Kingdom (UK), where a similar
532 study only found 199 ESBL-producing Enterobacteriaceae over the course of one year (0.5
533 isolates/day) from three hospital sites between 2008 to 2009 (49). A point-prevalence survey
534 conducted in a UK hospital in 2017 also identified no positive carbapenemase-producing
535 Enterobacteriaceae (CPE) from 540 samples (50).

536

537 Nearly all of the isolates presented in this study were characterised as multi-drug resistant
538 (MDR) on the basis of resistance to three or more antimicrobial drug classes (51). *K.*
539 *pneumoniae* was found to be particularly resistant, with a number of isolates carrying genes
540 to more than nine antibiotic classes. The only drug to which we did not observe extensive
541 resistance was *mcr* gene-mediated colistin resistance, which has been reported in animal
542 farming and agriculture in Vietnam (52-55). It is possible that the *mcr* gene has not yet
543 become disseminated to more urban areas of Vietnam, despite the use of colistin in clinical
544 settings. A limited number of isolates displayed mutational changes related to colistin
545 resistance, such as interruption of the *mgrB* gene in *K. pneumoniae* (56). We did not further
546 investigate the role of mutational colistin resistance as we did not have the capacity to
547 corroborate genotypic resistance with phenotypic measurements in this study.

548

549 Colonisation was found to be a large reservoir for AMR, with the majority of *E. coli* and
550 more than half of the *K. pneumoniae* isolated from stool samples, as has been documented

551 previously in Vietnamese hospitals (57). High community usage of antibiotics in Vietnam is
552 likely to promote colonisation with AMR bacteria, as prior treatment with antibiotics is
553 known to lead to colonisation (58). Colonisation itself has been identified as a risk factor for
554 subsequent infection (59-61), and has been previously documented in ICU patients in
555 southern Vietnam (62). Colonisation with AMR *E. coli* has also been identified as a risk for
556 transferral of resistance to other colonising pathogens, such as *Shigella* (63).

557

558 Infection control is critically important for reducing the risk of hospital-acquired infections
559 (HAIs) and mortality in ICUs. Here we found evidence for numerous recent transmission
560 events involving multiple patients, where *A. baumannii* and *K. pneumoniae* were more often
561 found in transmission clusters. *A. baumannii* is particularly problematic to control in hospital
562 environments owing to its ability to resist desiccation and cleaning (64) and to survive for
563 long periods of time on surfaces (65, 66). *K. pneumoniae* is also commonly responsible for
564 outbreaks in healthcare settings globally (67-69), and requires immediate and appropriate
565 intervention due to its propensity to be highly resistant and virulent (70). Detection and
566 prevention of AMR transmission in LMICs is difficult for a number of reasons. These include
567 limited capacity for microbiological testing, overcrowding of ICUs, inability to isolate ICU
568 patients, and inadequate staff training or knowledge of infection control procedures (71, 72).
569 The high level of AMR in this study would have made it difficult to discern specific clusters
570 using phenotypic methods alone. WGS enables accurate investigation of transmission events
571 but its use is limited by lack of infrastructure, expertise and high cost, particularly in
572 resource-constrained settings.

573

574 In addition to evidence for recent transmission between patients on the same ICU, we also
575 identified clusters involving patients from both hospital ICUs. This result was unexpected, as
576 there was no direct transfer of patients between the two ICUs. The most likely explanation
577 for these clusters is a source outside of the ICUs, such as other wards or other hospitals which
578 may have referred patients to ICU. Another possibility is that AMR strains may have been
579 acquired in the community, reflecting high rates antibiotic usage in the community and AMR
580 detection in livestock and food. Based on the similarity between lineages and AMR across
581 both ICUs, we suggest that transmission, particularly of the predominant *A. baumannii* and *K.*
582 *pneumoniae* lineages, is likely already circulating outside of the ICUs, where it is then further
583 propagated.

584

585 We acknowledge some limitations to our study. First, contamination of some of the isolates
586 prior to WGS necessitated additional filtering steps for the majority of samples. Secondly, we
587 did not extensively explore plasmid profiles amongst the samples because of the limitations
588 of short read sequence data. Thirdly, although serial samples were collected and cultured, we
589 selected single colony picks for sequencing. It is therefore possible that some diversity may
590 have been lost at different timepoints during the study sampling period. Finally, this study
591 focused on patient and environmental samples only. We were therefore unable to investigate
592 potential transmission events involving hospital staff and/or visitors.

593

594 Nevertheless, we present the largest prospective surveillance study of multidrug-resistant *E.*
595 *coli*, *A. baumannii* and *K. pneumoniae* in Vietnamese critical care patients to date. The
596 extensive transmission and AMR detected within and between ICU wards suggests dominant
597 circulating lineages of *A. baumannii* and *K. pneumoniae* existing both within hospitals, and
598 potentially in community settings in Vietnam. Further work should be conducted to expand
599 genomic surveillance in hospital and community settings to determine the levels of AMR and
600 prominent lineages in order to inform AMR control strategies in Vietnam.

601

602 *Data sharing*

603 Genome sequence data have been deposited in the European Nucleotide Archive (ENA)
604 under the Bioproject PRJEB29424. A list of the sample accession numbers is available in
605 Supplementary Dataset 1. Isolate genome assemblies (heterogenous sites masked and
606 unmasked) are available on Figshare under the following DOI:
607 [10.6084/m9.figshare.13303253](https://doi.org/10.6084/m9.figshare.13303253),
608 [10.6084/m9.figshare.13302728](https://doi.org/10.6084/m9.figshare.13302728).

609

610 *Ethical statement*

611 The study protocol was approved by the Scientific and Ethical Committees of the National
612 Hospital for Tropical Diseases and Bach Mai Hospital and by the University of Cambridge
613 Human Biology and Research Ethics Committee (reference: HBREC 2017.09). Written
614 informed consent was obtained from the patient or from their relative prior to enrolment in
615 the study.

616

617 *Declaration of interests*

618 All authors have no conflicts of interest to declare.

619

620 *Funding statement*

621 This work was funded by the Medical Research Council Newton Fund, the Vietnamese
622 Ministry of Science and Technology (HNQT/SPĐP/04.16), and the Wellcome Trust. LWR is
623 supported by an EMBL-EBI biomedical postdoctoral research fellowship. MET was
624 supported by a Clinician Scientist Fellowship (funded by the Academy of Medical Sciences
625 and the Health Foundation) and the NIHR Cambridge Biomedical Research Centre. The
626 funding source had no role in study design; in the collection, analysis, and interpretation of
627 data; in the writing of the report; and in the decision to submit the paper for publication.

628

629 **Author contributions**

630 Conceptualisation: LWR, ZI, MET

631 Data collection: FK, NTHM, LTH, NGB, DXC, LTH, NTH, TG, CB, HNT, BN, RvD, NVT

632 Sample processing: NTH, FK, JB, JH, TF

633 Methodology: LWR, ZI

634 Formal Analysis: LWR, ZI

635 Writing (original draft): LWR

636 Writing (review/editing): ZI, MET

637 Supervision: NVT, RvD, ZI, MET

638 Project administration: LTH, NVT, RvD, MET

639 Funding acquisition: MET, JP and NVK

640

641 **Acknowledgements**

642 The authors would like to thank the patients for participating in this study and the clinical and
643 laboratory staff of the National Hospital for Tropical Diseases and Bach Mai Hospital for
644 their assistance with this study. We also acknowledge the sequencing team at the Wellcome
645 Sanger Institute for their assistance with sequencing the samples including in the study.

646

647 **References**

- 648 1. R. M. Zellweger *et al.*, A current perspective on antimicrobial resistance in Southeast
649 Asia. *J Antimicrob Chemother* **72**, 2963-2972 (2017).
650 2. B. A. Walther *et al.*, Biodiversity and health: Lessons and recommendations from an
651 interdisciplinary conference to advise Southeast Asian research, society and policy.
652 *Infect Genet Evol* **40**, 29-46 (2016).

- 653 3. J. J. Carrique-Mas, M. Choisy, N. Van Cuong, G. Thwaites, S. Baker, An estimation
654 of total antimicrobial usage in humans and animals in Vietnam. *Antimicrob Resist*
655 *Infect Control* **9**, 16 (2020).
- 656 4. K. V. Nguyen *et al.*, Antibiotic use and resistance in emerging economies: a situation
657 analysis for Viet Nam. *BMC Public Health* **13**, 1158 (2013).
- 658 5. M. E. de Kraker, A. J. Stewardson, S. Harbarth, Will 10 Million People Die a Year
659 due to Antimicrobial Resistance by 2050? *PLoS Med* **13**, e1002184 (2016).
- 660 6. N. H. Tran *et al.*, Occurrence and risk assessment of multiple classes of antibiotics in
661 urban canals and lakes in Hanoi, Vietnam. *Sci Total Environ* **692**, 157-174 (2019).
- 662 7. S. Yamasaki, T. D. Le, M. Q. Vien, C. Van Dang, Y. Yamamoto, Prevalence of
663 extended-spectrum beta-lactamase-producing *Escherichia coli* and residual
664 antimicrobials in the environment in Vietnam. *Anim Health Res Rev* **18**, 128-135
665 (2017).
- 666 8. H. A. Duong *et al.*, Occurrence, fate and antibiotic resistance of fluoroquinolone
667 antibacterials in hospital wastewaters in Hanoi, Vietnam. *Chemosphere* **72**, 968-973
668 (2008).
- 669 9. N. T. Nhung *et al.*, Antimicrobial residues and resistance against critically important
670 antimicrobials in non-typhoidal *Salmonella* from meat sold at wet markets and
671 supermarkets in Vietnam. *Int J Food Microbiol* **266**, 301-309 (2018).
- 672 10. S. P. T. S. S. A. K. Anal, Addressing the antibiotic resistance and improving the food
673 safety in food supply chain (farm-to-fork) in Southeast Asia. *Food Control* **108**,
674 (2020).
- 675 11. T. Phodha, A. Riewpaiboon, K. Malathum, P. C. Coyte, Annual relative increased in
676 inpatient mortality from antimicrobial resistant nosocomial infections in Thailand.
677 *Epidemiol Infect* **147**, e133 (2019).
- 678 12. K. L. Wyres *et al.*, Genomic surveillance for hypervirulence and multi-drug resistance
679 in invasive *Klebsiella pneumoniae* from South and Southeast Asia. *Genome Med* **12**,
680 11 (2020).
- 681 13. M. D. Malchione, L. M. Torres, D. M. Hartley, M. Koch, J. L. Goodman,
682 Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review
683 and mapping of emerging and overlapping challenges. *Int J Antimicrob Agents* **54**,
684 381-399 (2019).
- 685 14. V. Le Minh *et al.*, In vitro activity of colistin in antimicrobial combination against
686 carbapenem-resistant *Acinetobacter baumannii* isolated from patients with ventilator-
687 associated pneumonia in Vietnam. *J Med Microbiol* **64**, 1162-1169 (2015).
- 688 15. D. J. Biedenbach *et al.*, Antimicrobial-resistant *Pseudomonas aeruginosa* and
689 *Acinetobacter baumannii* From Patients With Hospital-acquired or Ventilator-
690 associated Pneumonia in Vietnam. *Clin Ther* **38**, 2098-2105 (2016).
- 691 16. S. Quainoo *et al.*, Whole-Genome Sequencing of Bacterial Pathogens: the Future of
692 Nosocomial Outbreak Analysis. *Clin Microbiol Rev* **30**, 1015-1063 (2017).
- 693 17. M. S. Toleman *et al.*, Prospective genomic surveillance of methicillin-resistant
694 *Staphylococcus aureus* (MRSA) associated with bloodstream infection, England, 1
695 October 2012 to 30 September 2013. *Euro Surveill* **24**, (2019).
- 696 18. H. T. T. Phan *et al.*, Illumina short-read and MinION long-read WGS to characterize
697 the molecular epidemiology of an NDM-1 *Serratia marcescens* outbreak in Romania.
698 *J Antimicrob Chemother* **73**, 672-679 (2018).
- 699 19. E. M. Harrison *et al.*, Transmission of methicillin-resistant *Staphylococcus aureus* in
700 long-term care facilities and their related healthcare networks. *Genome Med* **8**, 102
701 (2016).

- 702 20. A. Santona *et al.*, Emergence of unusual vanA/vanB2 genotype in a highly mutated
703 vanB2-vancomycin-resistant hospital-associated *E. faecium* background in Vietnam.
704 *Int J Antimicrob Agents* **52**, 586-592 (2018).
- 705 21. H. Chung The *et al.*, A high-resolution genomic analysis of multidrug-resistant
706 hospital outbreaks of *Klebsiella pneumoniae*. *EMBO Mol Med* **7**, 227-239 (2015).
- 707 22. B. Berglund *et al.*, Colistin- and carbapenem-resistant *Klebsiella pneumoniae*
708 carrying *mcr-1* and *blaOXA-48* isolated at a paediatric hospital in Vietnam. *J*
709 *Antimicrob Chemother* **73**, 1100-1102 (2018).
- 710 23. B. Berglund *et al.*, Molecular and phenotypic characterization of clinical isolates
711 belonging to a KPC-2-producing strain of ST15 *Klebsiella pneumoniae* from a
712 Vietnamese pediatric hospital. *Antimicrob Resist Infect Control* **8**, 156 (2019).
- 713 24. . vol. 2020.
- 714 25. P. Ewels, M. Magnusson, S. Lundin, M. Kaller, MultiQC: summarize analysis results
715 for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047-3048
716 (2016).
- 717 26. D. E. Wood, J. Lu, B. Langmead, Improved metagenomic analysis with Kraken 2.
718 *Genome Biol* **20**, 257 (2019).
- 719 27. J. L. F. P. B. P. T. S. L. Salzberg, Bracken: estimating species abundance in
720 metagenomics data. *PeerJ Computer Science* **3:e104**, (2017).
- 721 28. A. Bankevich *et al.*, SPAdes: a new genome assembly algorithm and its applications
722 to single-cell sequencing. *J Comput Biol* **19**, 455-477 (2012).
- 723 29. A. Gurevich, V. Saveliev, N. Vyahhi, G. Tesler, QUAST: quality assessment tool for
724 genome assemblies. *Bioinformatics* **29**, 1072-1075 (2013).
- 725 30. D. H. Parks, M. Imelfort, C. T. Skennerton, P. Hugenholtz, G. W. Tyson, CheckM:
726 assessing the quality of microbial genomes recovered from isolates, single cells, and
727 metagenomes. *Genome Res* **25**, 1043-1055 (2015).
- 728 31. T. J. Treangen, B. D. Ondov, S. Koren, A. M. Phillippy, The Harvest suite for rapid
729 core-genome alignment and visualization of thousands of intraspecific microbial
730 genomes. *Genome Biol* **15**, 524 (2014).
- 731 32. N. J. Croucher *et al.*, Rapid phylogenetic analysis of large samples of recombinant
732 bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* **43**, e15 (2015).
- 733 33. A. Stamatakis, RAxML version 8: a tool for phylogenetic analysis and post-analysis
734 of large phylogenies. *Bioinformatics* **30**, 1312-1313 (2014).
- 735 34. J. Beghain, A. Bridier-Nahmias, H. Le Nagard, E. Denamur, O. Clermont,
736 ClermonTyping: an easy-to-use and accurate in silico method for *Escherichia* genus
737 strain phylotyping. *Microb Genom* **4**, (2018).
- 738 35. I. Letunic, P. Bork, Interactive Tree Of Life (iTOL) v4: recent updates and new
739 developments. *Nucleic Acids Res* **47**, W256-W259 (2019).
- 740 36. T. Seemann, Abriicate, Github <https://github.com/tseemann/abricate>.
- 741 37. M. Feldgarden *et al.*, Validating the AMRFinder Tool and Resistance Gene Database
742 by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection
743 of Isolates. *Antimicrob Agents Chemother* **63**, (2019).
- 744 38. M. Inouye *et al.*, SRST2: Rapid genomic surveillance for public health and hospital
745 microbiology labs. *Genome Med* **6**, 90 (2014).
- 746 39. L. Diancourt, V. Passet, A. Nemeč, L. Dijkshoorn, S. Brisse, The population structure
747 of *Acinetobacter baumannii*: expanding multiresistant clones from an ancestral
748 susceptible genetic pool. *PLoS One* **5**, e10034 (2010).
- 749 40. L. Diancourt, V. Passet, J. Verhoef, P. A. Grimont, S. Brisse, Multilocus sequence
750 typing of *Klebsiella pneumoniae* nosocomial isolates. *J Clin Microbiol* **43**, 4178-4182
751 (2005).

- 752 41. K. A. Jolley, J. E. Bray, M. C. J. Maiden, Open-access bacterial population genomics:
753 BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open*
754 *Res* **3**, 124 (2018).
- 755 42. J. Stimson *et al.*, Beyond the SNP Threshold: Identifying Outbreak Clusters Using
756 Inferred Transmissions. *Mol Biol Evol* **36**, 587-603 (2019).
- 757 43. J. F. Turton *et al.*, Identification of *Acinetobacter baumannii* by detection of the
758 blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol* **44**,
759 2974-2976 (2006).
- 760 44. T. V. D. Vu *et al.*, Antimicrobial susceptibility testing and antibiotic consumption
761 results from 16 hospitals in Viet Nam: The VINARES project 2012-2013. *J Glob*
762 *Antimicrob Resist* **18**, 269-278 (2019).
- 763 45. W. H. Organisation. (2017), vol. 2020.
- 764 46. T. Tada *et al.*, Dissemination of clonal complex 2 *Acinetobacter baumannii* strains co-
765 producing carbapenemases and 16S rRNA methylase ArmA in Vietnam. *BMC Infect*
766 *Dis* **15**, 433 (2015).
- 767 47. T. Tada *et al.*, Dissemination of Carbapenem-resistant *Klebsiella pneumoniae* clinical
768 isolates with various combinations of Carbapenemases (KPC-2, NDM-1, NDM-4, and
769 OXA-48) and 16S rRNA Methylases (RmtB and RmtC) in Vietnam. *BMC Infect Dis*
770 **17**, 467 (2017).
- 771 48. J. Chang *et al.*, Emergence of NDM-4-producing *Klebsiella pneumoniae* in a Korean
772 hospital due to a patient hospitalized in Vietnam and case review. *J Infect Chemother*
773 **25**, 909-912 (2019).
- 774 49. D. A. Enoch *et al.*, Epidemiology of extended-spectrum beta-lactamase-producing
775 Enterobacteriaceae in a UK district hospital; an observational study. *J Hosp Infect* **81**,
776 270-277 (2012).
- 777 50. H. J. Wilson *et al.*, Point-prevalence survey of carbapenemase-producing
778 Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a
779 university teaching hospital in the UK. *J Hosp Infect* **100**, 35-39 (2018).
- 780 51. A. P. Magiorakos *et al.*, Multidrug-resistant, extensively drug-resistant and pandrug-
781 resistant bacteria: an international expert proposal for interim standard definitions for
782 acquired resistance. *Clin Microbiol Infect* **18**, 268-281 (2012).
- 783 52. Y. Yamamoto *et al.*, Wide dissemination of colistin-resistant *Escherichia coli* with the
784 mobile resistance gene mcr in healthy residents in Vietnam. *J Antimicrob Chemother*
785 **74**, 523-524 (2019).
- 786 53. T. Yamaguchi *et al.*, The presence of colistin resistance gene mcr-1 and -3 in ESBL
787 producing *Escherichia coli* isolated from food in Ho Chi Minh City, Vietnam. *FEMS*
788 *Microbiol Lett* **365**, (2018).
- 789 54. N. V. Trung *et al.*, Zoonotic Transmission of mcr-1 Colistin Resistance Gene from
790 Small-Scale Poultry Farms, Vietnam. *Emerg Infect Dis* **23**, 529-532 (2017).
- 791 55. S. Malhotra-Kumar *et al.*, Colistin-resistant *Escherichia coli* harbouring mcr-1
792 isolated from food animals in Hanoi, Vietnam. *Lancet Infect Dis* **16**, 286-287 (2016).
- 793 56. L. Poirel *et al.*, The mgrB gene as a key target for acquired resistance to colistin in
794 *Klebsiella pneumoniae*. *J Antimicrob Chemother* **70**, 75-80 (2015).
- 795 57. D. M. Tran *et al.*, High prevalence of colonisation with carbapenem-resistant
796 Enterobacteriaceae among patients admitted to Vietnamese hospitals: Risk factors and
797 burden of disease. *J Infect* **79**, 115-122 (2019).
- 798 58. J. Ruiz *et al.*, Influence of antibiotic pressure on multi-drug resistant *Klebsiella*
799 *pneumoniae* colonisation in critically ill patients. *Antimicrob Resist Infect Control* **8**,
800 38 (2019).

- 801 59. C. M. Manaia, Assessing the Risk of Antibiotic Resistance Transmission from the
802 Environment to Humans: Non-Direct Proportionality between Abundance and Risk.
803 *Trends Microbiol* **25**, 173-181 (2017).
- 804 60. M. E. Flokas, S. A. Karageorgos, M. Detsis, M. Alevizakos, E. Mylonakis,
805 Vancomycin-resistant enterococci colonisation, risk factors and risk for infection
806 among hospitalised paediatric patients: a systematic review and meta-analysis. *Int J*
807 *Antimicrob Agents* **49**, 565-572 (2017).
- 808 61. J. Asir *et al.*, Simultaneous gut colonisation and infection by ESBL-producing
809 *Escherichia coli* in hospitalised patients. *Australas Med J* **8**, 200-207 (2015).
- 810 62. D. B. Thuy, Colonisation and Infection with Antibiotic-Resistant Organisms in
811 Patients in the Adult Intensive Care Unit, Hospital for Tropical Diseases, Ho Chi
812 Minh City, Vietnam. *PhD thesis, University of Oxford*, (2018).
- 813 63. P. Thanh Duy *et al.*, Commensal *Escherichia coli* are a reservoir for the transfer of
814 XDR plasmids into epidemic fluoroquinolone-resistant *Shigella sonnei*. *Nat Microbiol*
815 **5**, 256-264 (2020).
- 816 64. A. Y. Peleg, H. Seifert, D. L. Paterson, *Acinetobacter baumannii*: emergence of a
817 successful pathogen. *Clin Microbiol Rev* **21**, 538-582 (2008).
- 818 65. P. J. van den Broek *et al.*, Epidemiology of multiple *Acinetobacter* outbreaks in The
819 Netherlands during the period 1999-2001. *Clin Microbiol Infect* **12**, 837-843 (2006).
- 820 66. A. Jawad, H. Seifert, A. M. Snelling, J. Heritage, P. M. Hawkey, Survival of
821 *Acinetobacter baumannii* on dry surfaces: comparison of outbreak and sporadic
822 isolates. *J Clin Microbiol* **36**, 1938-1941 (1998).
- 823 67. E. S. Snitkin *et al.*, Tracking a hospital outbreak of carbapenem-resistant *Klebsiella*
824 *pneumoniae* with whole-genome sequencing. *Sci Transl Med* **4**, 148ra116 (2012).
- 825 68. D. Marchaim *et al.*, Outbreak of colistin-resistant, carbapenem-resistant *Klebsiella*
826 *pneumoniae* in metropolitan Detroit, Michigan. *Antimicrob Agents Chemother* **55**,
827 593-599 (2011).
- 828 69. D. Gu *et al.*, A fatal outbreak of ST11 carbapenem-resistant hypervirulent *Klebsiella*
829 *pneumoniae* in a Chinese hospital: a molecular epidemiological study. *Lancet Infect*
830 *Dis* **18**, 37-46 (2018).
- 831 70. K. E. Holt *et al.*, Genomic analysis of diversity, population structure, virulence, and
832 antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health.
833 *Proc Natl Acad Sci U S A* **112**, E3574-3581 (2015).
- 834 71. M. Vukoja *et al.*, A survey on critical care resources and practices in low- and
835 middle-income countries. *Glob Heart* **9**, 337-342 e331-335 (2014).
- 836 72. M. J. Schultz *et al.*, Current challenges in the management of sepsis in ICUs in
837 resource-poor settings and suggestions for the future. *Intensive Care Med* **43**, 612-624
838 (2017).
- 839